As Pfizer Closes Door On Exubera, Has Window Opened For Others?
Executive Summary
Pfizer's decision to terminate its Exubera program - the first inhaled insulin product to hit the market - could provide an opportunity for other drug makers looking to step into the market, especially those prepared to address obstacles illuminated by Pfizer
You may also be interested in...
Ghosts of Exubera Haunt Afrezza As Lung Function, Cancer Concerns Weigh Heavily
FDA advisory committee review of MannKind’s inhaled insulin revisits safety issues that troubled Pfizer’s first-of-its-kind product, including a potential lung cancer risk and declines in pulmonary function.
NDA Submitted, MannKind’s Inhaled Insulin Faces Next Test: Finding A Partner
Deal terms may show pharma’s faith that Afresa can beat the stigma of Pfizer’s fizzled Exubera.
NDA Almost Ready, MannKind Exubera(nt) About Chances For Inhaled-Insulin Partner
Despite safer-seeming profile, many skeptical of Afresa after flameout of Pfizer’s product.